231 related articles for article (PubMed ID: 2363120)
1. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
2. [The pharmacokinetics and pharmacodynamics of recombinant hirudin-2 nasal spray].
Zhang YJ; Zhang Q; Hou JL; Wang XL; Chen MX
Yao Xue Xue Bao; 2006 Mar; 41(3):268-71. PubMed ID: 16759001
[TBL] [Abstract][Full Text] [Related]
3. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
Nawa K; Itani T; Ono M; Sakano K; Marumoto Y; Iwamoto M
Thromb Haemost; 1992 Mar; 67(3):366-70. PubMed ID: 1322570
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
[TBL] [Abstract][Full Text] [Related]
6. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological survey of recombinant hirudin.
Markwardt F; Fink G; Kaiser B; Klöcking HP; Nowak G; Richter M; Stürzebecher J
Pharmazie; 1988 Mar; 43(3):202-7. PubMed ID: 3380865
[TBL] [Abstract][Full Text] [Related]
8. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes.
Meng M; Liu Y; Wang YB; Wang JC; Zhang H; Wang XQ; Zhang X; Lu WL; Zhang Q
J Control Release; 2008 Jun; 128(2):113-9. PubMed ID: 18423766
[TBL] [Abstract][Full Text] [Related]
9. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
10. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo.
Talbot MD; Ambler J; Butler KD; Findlay VS; Mitchell KA; Peters RF; Tweed MF; Wallis RB
Thromb Haemost; 1989 Feb; 61(1):77-80. PubMed ID: 2749592
[TBL] [Abstract][Full Text] [Related]
11. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
12. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin.
Dickneite G; Czech J; Keuper H
Circ Shock; 1994 Apr; 42(4):183-9. PubMed ID: 8055664
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
14. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
15. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
[TBL] [Abstract][Full Text] [Related]
16. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
Lindhout T; Blezer R; Hemker HC
Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
Kaiser B; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
[TBL] [Abstract][Full Text] [Related]
18. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
19. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
20. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization.
Liu Y; Lu WL; Wang JC; Zhang X; Zhang H; Wang XQ; Zhou TY; Zhang Q
J Control Release; 2007 Feb; 117(3):387-95. PubMed ID: 17207884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
